Cancer 2013 July-6

 

Detection of trastuzumab efficacy using H-1 MRI ex vivo of breast cancer cells.

Med Chem Res.2012 Sep;21(9):2316-2319.

Dorota Bartusik, Boguslaw Tomanek

Natl Res Council Canada, Inst Biodiagnost W, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada

Abstract

This study is aimed on Magnetic resonance imaging (MRI) modalities for monitoring Herceptin (trastuzumab) efficacy in breast cancer cells ex vivo. The efficacy profile of trastuzumab (0.010 μg/ml) was examined using T2 relaxivity measurements prior to and after 24, 48, and 72 h treatment. The untreated MCF-7 cells were considered as a control. MRI results show early tumor response to treatment while comparing pre- and post-treatment T2. The changes of T2 MRI correspond to tumor growth inhibition. The study shows that MRI can be used for the non-invasive monitoring of cancer cells’ death caused by immuno-targeting in preclinical testing of efficacy and treatment regimens.

Full text

Multiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier SchönmannMultiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier Schönmann